Biomedreports article on BIEL (very positive)

Any serious BIEL investor should take some time and read this entire article by Biomedreports.

http://biomedreports.com/articles/most-popular/17424-banking-on-biels-upcoming-study-results-against-tylenol.html

Few Excerpts from the article :

“We found newspaper articles dating back over twenty years in which scientists urged stronger warning labels on every bottle of acetaminophen, based on evidence that countless Americans unwittingly took toxic doses that harmed their livers“

“That push and the results of a soon to be released study by Bioelectronics Corp. (OTC:BIEL) set the table for an intriguing penny play in the coming days. The company made this year’s 10 Stock BioMed Momentum Index, with investors riding the wave of excitement about the technology and pending FDA decisions, but the upcoming news flash will likely make shares of the micro-cap company run up once again. “

“Company officials won’t yet officially disclose what the study results will reveal, but there are strong hints in what was released as part of the pilot section of the study last month. That Institutional Review Board (IRB) supervised study is directed at comparing the effects of the company’s ActiPatch® Therapy to acetaminophen in the form of Extra Strength Tylenol® for the treatment of delayed onset muscle soreness (DOMS). “

 

Advertisement